Drug research, cilt.65, sa.5, ss.272-80, 2015 (Scopus)
Background: This study was designed to investigate the protective effects of bosentan an orally active non-peptide mixed ETA/ETB receptor antagonist, on liver injury in streptozotocin-induced diabetic rats.